Curaleaf Stock Forecast, Price & News

Curaleaf (OTCMKTS:CURLF) Frequently Asked Questions

Is Curaleaf a buy right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Curaleaf in the last twelve months. There are currently 1 sell rating, 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Curaleaf stock.
View analyst ratings for Curaleaf or view top-rated stocks.

How has Curaleaf's stock price been impacted by COVID-19?

Curaleaf's stock was trading at $4.42 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CURLF stock has increased by 115.9% and is now trading at $9.5414.
View which stocks have been most impacted by COVID-19.

Are investors shorting Curaleaf?

Curaleaf saw a increase in short interest in November. As of November 15th, there was short interest totaling 1,379,800 shares, an increase of 29.2% from the October 31st total of 1,068,200 shares. Based on an average trading volume of 2,363,500 shares, the short-interest ratio is currently 0.6 days.
View Curaleaf's Short Interest.

How were Curaleaf's earnings last quarter?

Curaleaf Holdings, Inc. (OTCMKTS:CURLF) released its quarterly earnings data on Monday, March, 8th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.02) by $0.03.
View Curaleaf's earnings history.

What price target have analysts set for CURLF?

10 equities research analysts have issued 12-month price objectives for Curaleaf's shares. Their forecasts range from $16.00 to $32.00. On average, they anticipate Curaleaf's share price to reach $22.38 in the next year. This suggests a possible upside of 134.5% from the stock's current price.
View analysts' price targets for Curaleaf or view top-rated stocks among Wall Street analysts.

Who are Curaleaf's key executives?

Curaleaf's management team includes the following people:

• Joseph D. Bayern, President & Chief Executive Officer
• Neil P. Davidson, Chief Operating Officer
• Ranjan Kalia, Chief Financial Officer
• Robert Winnicki, Senior VP-Research & Product Development
• James Shorris, Chief Compliance Officer

Who are some of Curaleaf's key competitors?

Some companies that are related to Curaleaf include Abacus Health Products (ABAHF), Acreage (ACRGF), Alliance Growers (ACG), Althea Group (AGH), Applied Biosciences (APPB), AusCann Group (AC8), Ayr Strategies (AYRSF), Bio-Rad Laboratories (BIO), Blueberries Medical (BBM), Can B (CANB), Cannara Biotech (LOVE), CannPal Animal Therapeutics (CP1), Cansortium (CNTMF), Chalice Brands (GLDFF) and Charlotte's Web (CWBHF).
View all of CURLF's competitors.

What is Curaleaf's stock symbol?

Curaleaf trades on the OTCMKTS under the ticker symbol "CURLF."

How do I buy shares of Curaleaf?

Shares of CURLF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Curaleaf's stock price today?

One share of CURLF stock can currently be purchased for approximately $9.54.

What is Curaleaf's official website?

The official website for Curaleaf is www.curaleaf.com.

Where are Curaleaf's headquarters?

Curaleaf is headquartered at 301 Edgewater Place, Wakefield, MA 01880.

How can I contact Curaleaf?

Curaleaf's mailing address is 301 Edgewater Place, Wakefield, MA 01880. The company can be reached via phone at (781) 451-0150.